论文部分内容阅读
目的:通过建立人类幽门螺杆菌(helicobacter pylori,HP)BALB/C 小鼠模型,研究免疫联合中药胃泰胶囊在治疗 HP 感染中的作用。方法:通过灌喂途径建立人类 HP BALB/C 小鼠模型,把已感染上 HP 的小鼠分为6组:A 组给予尿素酶加霍乱毒素 B 亚单位(CTB)加羟磷灰石(HAP)、B 组给予尿素酶加 CTB 加HAP 加中药胃泰、C 组给予胃泰、D 组给予尿素酶、E 组给予 CTB 加 HAP,F 组为空白对照组;其中尿素酶每周1次共4周,胃泰胶囊每天1次共2周,治疗结束后4周将小鼠处死,取胃粘膜行尿素酶试验和 Giemsa 染色,检查 HP 感染情况。结果:各组 HP 的根除率分别为:A 组61.5%、B 组75.0%、C 组53.8%,D、E、F 组均为0:A、B、C 组小鼠胃粘膜的炎症明显减轻。结论:尿素酶联合中药胃泰胶囊对幽门螺杆菌感染有较好的清除作用,并能较好减轻胃粘膜炎症。
OBJECTIVE: To study the effect of combined immunotherapy with Wei Tai Capsule in the treatment of HP infection by establishing human BALB / C mouse model of Helicobacter pylori (HP). Methods: The human HP BALB / C mouse model was established by the method of feeding. The mice infected with HP were divided into 6 groups: group A received urease plus cholera toxin B subunit (CTB) plus hydroxyapatite (HAP ), B group were given urease plus CTB plus HAP plus Chinese medicine Wei Tai, C group given Wei Tai, D group given urease, E group given CTB plus HAP, F group as a blank control group; 4 weeks, Weitai capsules once a day for 2 weeks, 4 weeks after treatment, the mice were sacrificed, the gastric mucosa were taken urease test and Giemsa staining to check HP infection. Results: The eradication rates of HP in each group were 61.5% in group A, 75.0% in group B and 53.8% in group C, respectively. The gastric mucosal inflammation in group A, B and C were significantly reduced . Conclusion: The combination of urease and Wei Tai Capsule has a good effect of removing Helicobacter pylori infection and can alleviate gastric mucosal inflammation.